671 related articles for article (PubMed ID: 26306400)
1. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
8. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
Debruyne F; Boyle P; Calais Da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman CC
Eur Urol; 2004 Jun; 45(6):773-9; disucssion 779-80. PubMed ID: 15149751
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
Debruyne F; Boyle P; Calais da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman C
Prog Urol; 2004 Jun; 14(3):326-31. PubMed ID: 15373174
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.
Alcaraz A; Rodríguez-Antolín A; Carballido-Rodríguez J; Castro-Díaz D; Medina-Polo J; Fernández-Gómez JM; Ficarra V; Palou J; Ponce de León Roca J; Angulo JC; Esteban-Fuertes M; Cózar-Olmo JM; Pérez-León N; Molero-García JM; Fernández-Pro Ledesma A; Brenes-Bermúdez FJ; Manasanch J
Sci Rep; 2021 Sep; 11(1):19401. PubMed ID: 34588509
[TBL] [Abstract][Full Text] [Related]
12. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
MacDonald R; Tacklind JW; Rutks I; Wilt TJ
BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
14. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
[TBL] [Abstract][Full Text] [Related]
15. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
16. Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.
Alcaraz A; Rodríguez-Antolín A; Carballido-Rodríguez J; Castro-Díaz D; Esteban-Fuertes M; Cózar-Olmo JM; Ficarra V; Medina-López R; Fernández-Gómez JM; Angulo JC; Medina-Polo J; Brenes-Bermúdez FJ; Molero-García JM; Fernández-Pro-Ledesma A; Manasanch J; The Qualiprost Study Group OBO
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32917008
[TBL] [Abstract][Full Text] [Related]
17. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
Ryu YW; Lim SW; Kim JH; Ahn SH; Choi JD
Urol Int; 2015; 94(2):187-93. PubMed ID: 25614155
[TBL] [Abstract][Full Text] [Related]
19. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
[TBL] [Abstract][Full Text] [Related]
20. [Alpha-blockers or hexanic extract of Serenoa repens for 6 months: sub-analysis of the PERSAT study].
de la Taille A; Chalret du Rieu Q; Dialla O; Bardin L
Prog Urol; 2023 Feb; 33(2):66-72. PubMed ID: 36207246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]